Quest Diagnostics to Purchase Outreach Lab Assets From Health System OhioHealth
Citi Upgrades Illumina, Quest, Agilent to Buy, Downgrades Avantor
Express News | Quest Diagnostics Inc: Financial Details of Transaction Were Not Disclosed.
Express News | Quest Diagnostics to Acquire Outreach Laboratory Services of Ohiohealth
Quest Diagnostics Raised to Buy From Neutral by Citigroup
Quest Diagnostics Raised to Buy From Neutral by
Quest Diagnostics Price Target Raised to $165.00/Share From $145.00 by Citigroup
Quest Diagnostics Price Target Raised to $165.00/Share From $145.00 by
Express News | Quest Diagnostics Inc : Citigroup Raises to Buy From Neutral; Raises Target Price to $165 From $145
Citi Upgrades Quest Diagnostics(DGX.US) to Buy Rating, Raises Target Price to $165
Citi analyst Patrick B Donnelly upgrades $Quest Diagnostics(DGX.US)$ to a buy rating, and adjusts the target price from $145 to $165.According to TipRanks data, the analyst has a success rate of 45.7%
Citigroup Upgrades Quest Diagnostics to Buy From Neutral, Adjusts Price Target to $165 From $145
Quest Diagnostics (DGX) has an average outperform rating and a price target range of $136 to $160, according to analysts polled by Capital IQ.Price: 137.78, Change: -0.58, Percent Change: -0.42
Drug Middlemen Pay Higher Prices to Their Own Pharmacies, Says FTC
(July 9): Drug middlemen paid their own mail-order pharmacies as much as 200 times more than the price at rival pharmacies for commonly prescribed cancer drugs, allowing them to bring in at least US$1 billion (RM4.71 billion) in excess revenue and potentially raising the costs to patients, the US Federal Trade Commission (FTC) found in an interim study.
Analysts' Opinions Are Mixed on These Healthcare Stocks: CureVac (CVAC), Insmed (INSM) and Quest Diagnostics (DGX)
Express News | Quest Diagnostics Inc : Baird Raises Target Price to $153 From $145
Health Care Roundup: Market Talk
The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET. 1815 GMT - Quest Diagnostics' long-rumored acquisition of Life
Quest Diagnostics' LifeLabs Buy Could Boost Earnings by 4% to 5% -- Market Talk
1145 ET - Quest Diagnostics acquiring LifeLabs could be 4% to 5% accretive to its earnings in fiscal 2025, UBS analysts say, assuming the lab-test provider grows 5% annually and Quest uses a fairly eq
S&P Global To Rally More Than 13%? Here Are 10 Top Analyst Forecasts For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.Truist Secu
Quest Diagnostics Is Maintained at Neutral by Baird
Quest Diagnostics Is Maintained at Neutral by Baird
Baird Maintains Quest Diagnostics(DGX.US) With Hold Rating, Raises Target Price to $153
Baird analyst Eric Coldwell maintains $Quest Diagnostics(DGX.US)$ with a hold rating, and adjusts the target price from $145 to $153.According to TipRanks data, the analyst has a success rate of 52.4%
Quest Diagnostics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/05/2024 8.59% Baird $145 → $153 Maintains Neutral 05/30/2024 10.01% JP Morgan $152 → $155 Maintains Neu
What You Can Learn From Quest Diagnostics Incorporated's (NYSE:DGX) P/E
There wouldn't be many who think Quest Diagnostics Incorporated's (NYSE:DGX) price-to-earnings (or "P/E") ratio of 18.6x is worth a mention when the median P/E in the United States is similar at about
Baird Adjusts Price Target on Quest Diagnostics to $153 From $145, Maintains Neutral Rating
Quest Diagnostics (DGX) has an average rating of outperform and price targets ranging from $136 to $160, according to analysts polled by Capital IQ. Price: 142.56, Change: +1.66, Percent Change: +1.18